scholarly journals Cutaneous Malignancies in Tattoos, a Case Series of Six Patients

2021 ◽  
Vol 28 (6) ◽  
pp. 4721-4737
Author(s):  
Marike Leijs ◽  
Hannah Schaefer ◽  
Albert Rübben ◽  
Claudio Cacchi ◽  
Thomas Rustemeyer ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Immune Therapy ◽  
Case Series ◽  
Epidemiologic Studies ◽  
Extensive Literature ◽  
Epidemiological Evidence ◽  
Literature Research ◽  
Skin Cancers ◽  
Induced Tumors ◽  
Tattoo Inks

Background: A variety of side effects following the tattooing of the skin were reported over the years. Analytical studies showed that some tattoo inks contain harmful compounds. Methods: We presented six patient cases with cutaneous malignancies in tattooed skin and performed an extensive literature research. Results: Two patients with black ink tattoos that were diagnosed with malignant melanoma raises the number of described cases to 36 patients. One of the patients developed an immunologic reaction limited to the tattoo area after treatment with a targeted immune therapy. In the other patient, the malignancy (malignant melanoma) was fatal. Basal cell carcinoma was seen in four patients with tattoos containing varying ink colors (black, green, red). This increased the number of described patient cases to 18. Although some ink components and their cleavage products have carcinogenic properties, epidemiological evidence for a causative correlation fails. Further epidemiologic studies on tattoos and malignancies, as well as on the appearance of naevi in tattoos, are necessary. Determining the type of mutation might be helpful to separate sun-induced tumors from skin cancers due to other pathogenic mechanisms.

scholarly journals Multiple Pigmented Bowen’s Disease: A Diagnostic and Therapeutic Dilemma

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Pratik Gahalaut ◽  
Madhur Kant Rastogi ◽  
Nitin Mishra ◽  
Sandhya Chauhan
Keyword(s):  
Malignant Melanoma ◽  
The Body ◽  
Therapeutic Trial ◽  
Extensive Literature ◽  
Literature Research ◽  
Therapeutic Challenge ◽  
Precancerous Condition ◽  
Pigmented Lesions ◽  
Type V ◽  
Indian Male

Bowens' disease (BD) is a precancerous condition of skin and/or mucosa with a predilection towards sun-exposed areas. Extensive literature research failed to reveal any case of multiple pigmented BD in type V Fitzpatrick skin. Multiple BD is a therapeutic challenge with a tendency to recur. Here we present an otherwise healthy Indian male having multiple pigmented lesions of BD on sun-protected sites of the body mimicking malignant melanoma. These lesions were refractory to treatment with different modalities. This paper is an attempt to review the available literature regarding the pigmented variant of multiple BD. Rationale for a therapeutic trial of UVB therapy for multiple arsenic induced BD is also discussed.

Foot and Ankle Injections in Athletes

2021 ◽  
pp. 194173812110036
Author(s):  
Jonathan K. Ochoa ◽  
Christopher E. Gross ◽  
Robert B. Anderson ◽  
Andrew R. Hsu
Keyword(s):  
English Language ◽  
Platelet Rich Plasma ◽  
Empirical Studies ◽  
Autologous Blood ◽  
Case Series ◽  
Placental Tissue ◽  
Ankle Injuries ◽  
Extensive Literature ◽  
Foot And Ankle ◽  
Level Of Evidence

Context: Injections are commonly used by health care practitioners to treat foot and ankle injuries in athletes despite ongoing questions regarding efficacy and safety. Evidence Acquisition: An extensive literature review was performed through MEDLINE, Google Scholar, and EBSCOhost from database inception to 2021. Keywords searched were injections, athletes, sports, foot and ankle, corticosteroids, platelet-rich plasma, and placental tissue. Search results included articles written in the English language and encompassed reviews, case series, empirical studies, and basic science articles. Study Design: Clinical review. Level of Evidence: Level 4. Results: Corticosteroids, platelet-rich plasma/autologous blood, anesthetic, and placental tissue injections are commonly used in the treatment of foot and ankle injuries. Primary indications for injections in athletes include plantar fasciitis, Achilles tendinosis, isolated syndesmotic injury, and ankle impingement with varying clinical results. Conclusions: Despite promising results from limited case series and comparative studies, the data for safety and efficacy of injections for foot and ankle injuries in athletes remain inconclusive.

Detection of malignant melanoma and other skin cancers during the Euromelanoma Screening Day, 2003

2004 ◽  
Vol 14 (4) ◽  
pp. A16
Author(s):  
A. J. Stratigos ◽  
S. Kedicoglou ◽  
O. Papadopoulos ◽  
G. Haidemenos ◽  
A. Katsambas
Keyword(s):  
Malignant Melanoma ◽  
Skin Cancers

scholarly journals Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

2021 ◽  
Vol 12 ◽  
Author(s):  
Lili Cheng ◽  
Qi Song ◽  
Mengke Liu ◽  
Yan Wang ◽  
Hongmei Yi ◽  
...  
Keyword(s):  
Standard Treatment ◽  
Hematological Malignancy ◽  
Checkpoint Inhibitor ◽  
Immune Therapy ◽  
Case Series ◽  
The Elderly ◽  
Plasmablastic Lymphoma ◽  
Successful Management ◽  
Immunodeficiency Virus ◽  
Specific Standard

Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant status, or immunosenescence. Given its rarity, there is no specific standard treatment for PBL. However, small case series have shown that intensive chemotherapies combined with anti-myeloma agents such as bortezomib and lenalidomide were effective in treating PBL. Unfortunately, some fragile patients could not tolerate intensive chemotherapeutic regimens, especially the elderly patients. Here we presented a 76-year-old female PBL patient refractory to miniCHOP regimen combined with bortezomib but achieved complete remission when treated with tislelizumab combined with lenalidomide, indicating that immune therapy may be a potential treatment for PBL. To our knowledge, this is the first chemoresistant PBL patient that has been successfully treated with checkpoint inhibitor plus lenalidomide, thus providing new insight towards PBL management.

Rituximab for Eosinophilic Granulomatosis with Polyangiitis: a Systematic Review of Observational Studies

Rheumatology ◽  
2021 ◽  
Author(s):  
Vincenzo G Menditto ◽  
Giulia Rossetti ◽  
Diletta Olivari ◽  
Alessia Angeletti ◽  
Marco Rocchi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Granulomatosis With Polyangiitis ◽  
Case Reports ◽  
Case Series ◽  
Biologic Agents ◽  
Cochrane Library ◽  
Eosinophilic Granulomatosis With Polyangiitis ◽  
Extensive Literature ◽  
Eosinophilic Granulomatosis

Abstract Objective to analyze the available evidence about the use of rituximab (RTX) and other biologic agents in Eosinophilic Granulomatosis with Polyangiitis (EGPA) patients and to provide useful findings to inform the design of future, reliable clinical trials. Methods A systematic review was performed. A systematic search was conducted in PubMed/MEDLINE, Scopus, Web of Science and the Cochrane library databases and an extensive literature search on other biologic agents. Results 45 papers pertinent to our questions were found: 16 retrospective cohort studies, 8 case series, 3 prospective cohort studies and 18 single case reports, for a total of 368 EGPA patients. More than 80% of evaluable patients achieved complete or partial remission with a tendency towards a higher rate of complete response in pANCA positive subgroup. Conclusion Although the majority of the evaluable EGPA patients treated with RTX appears to achieve complete remission, we strongly believe that a number of sources of heterogeneity impairs a clear interpretation of results and limits their transferability in clinical practice. Differences in design, enrollment criteria, outcome definition and measurement make a comparison among data obtained from studies on RTX and other biologic agents unreliable.

Dermatology

2020 ◽  
pp. 432-461
Author(s):  
Sanju Arianayagam
Keyword(s):  
Malignant Melanoma ◽  
Skin Disease ◽  
Acne Vulgaris ◽  
Systemic Disease ◽  
Skin Infections ◽  
Drug Eruptions ◽  
Skin Cancers ◽  
Common Skin

This chapter in the Oxford Handbook of Clinical Specialties explores the specialty of dermatology. It works up from the basics of dermatology through describing a lesion and patterns of skin disease to itch and signs of systemic disease. Cancer is reviewed, including common skin cancers and premalignant tumours and malignant melanoma. Psoriasis is explored, along with eczema, skin infections, acne vulgaris, rosacea, drug eruptions, photosensitivity, urticaria, ulcers, HIV, infestations, and psychodermatoses.

Dermatology

2016 ◽  
pp. 582-611
Author(s):  
Andrew Baldwin ◽  
Nina Hjelde ◽  
Charlotte Goumalatsou ◽  
Gil Myers
Keyword(s):  
Malignant Melanoma ◽  
Acne Vulgaris ◽  
Systemic Disease ◽  
Pyogenic Granuloma ◽  
Skin Disorders ◽  
Venous Ulcers ◽  
Drug Eruptions ◽  
Skin Cancers ◽  
Common Skin ◽  
Skin Signs

This chapter explores dermatology. It includes history and examination, creams and ointments, describing a lesion, patterns of skin disease, itch, skin signs in systemic disease, common skin cancers, malignant melanoma, moles, psoriasis, eczema (dermatitis), skin infections (fungi, bacteria, viruses), acne vulgaris, rosacea, drug eruptions, specific skin disorders (pemphigus and pemphigoid, strawberry naevus, pyogenic granuloma, lichen planus, pityriasis rosea, alopecia, photosensitivity, urticaria), venous ulcers, pressure sores, skin disorders and HIV, infestations, and psychodermatoses.

scholarly journals Tumors associated with radiotherapy: a case series

2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Mauricio Garcia ◽  
Dary L. Hernandez ◽  
Sara Mendoza ◽  
Nelson Buelvas ◽  
Angelina Alvarez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Basal Cell Carcinoma ◽  
Cancer Treatment ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Case Series ◽  
Breast Cancer Treatment ◽  
Induced Tumors ◽  
Incidence And Mortality

Abstract Background Breast cancer is the cancer with the highest incidence and mortality worldwide. Its treatment is multidisciplinary with surgery, systemic therapy, and radiotherapy. In Colombia, according to Globocan 2018, there is an age-standardized incidence rate of 44 per 100,000 women. Radiotherapy improves local and regional control in patients with breast cancer, and it could even improve relapse-free survival and overall survival in patients with nodal disease. The toxicity of this treatment in most cases is mild and transient, but in a low percentage of patients, radiotherapy-induced tumors may develop. Case presentation Seven Colombian patients treated for breast cancer at our institution developed radiotherapy-induced tumors between 2008 and 2018. The median age was 54.4 (range 35–72) years. Six patients had locally advanced tumors at the time breast cancer was diagnosed, and all of them received neoadjuvant or adjuvant chemotherapy and radiotherapy. The radiotherapy-induced tumors were five sarcomas, one of which was a well-differentiated angiosarcomatous vascular lesion with negative c-Myc (benign lesion), and the remaining patient had basal cell carcinoma associated with radiotherapy. Conclusions Sarcomas are the most common radiotherapy-induced tumors after breast cancer treatment. These are rare, aggressive tumors and represent between 0.5% and 5.5% of all sarcomas. Basal cell carcinoma has also been associated with breast cancer treatment. The management is individualized and multimodal, including surgical resection and chemotherapy. Different studies have shown that radiation therapy is a risk factor for the development of soft tissue tumors.

Coexistent Malignant Melanoma and Renal Cell Carcinoma

2009 ◽  
Vol 95 (4) ◽  
pp. 518-520 ◽  
Author(s):  
Balaji Venugopal ◽  
TR Jeffry Evans
Keyword(s):  
Renal Cell Carcinoma ◽  
Malignant Melanoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Mass ◽  
Past History ◽  
Imaging Techniques ◽  
Case Series ◽  
Second Primary ◽  
Increased Risk

Patients with malignant melanoma are at an increased risk of developing subsequent primary melanomas and also nonmelanoma cutaneous cancers. Several studies have reported an association between malignant melanoma and breast cancer, bladder cancer, colorectal cancer, neuroectodermal tumours, non-Hodgkin's lymphoma, leukaemia and renal cell carcinoma. We report a case series of patients with a diagnosis of malignant melanoma who also developed a renal mass. In two of these cases, the renal mass became apparent on diagnostic imaging as part of the staging investigations at the time of initial diagnosis of the malignant melanoma. In both of these cases, biopsy of the renal mass confirmed the presence of a separate primary renal cell carcinoma which had presented concurrently with the malignant melanoma. A third case presented with bone metastases ten years after excision of a thin melanoma. Further imaging revealed pulmonary metastases and a renal mass, biopsy of which confirmed renal cell carcinoma. In contrast, a fourth patient underwent a right nephrectomy for a renal mass having presented with abdominal discomfort. The histology of this lesion was in keeping with metastatic melanoma, and the patient's past history included a diagnosis of ocular melanoma eight years prior to the development of metastatic disease in the right kidney. Survival rates for patients with many types of malignant disease are improving, and there have been significant advances in clinical imaging techniques. Consequently the development and detection of a second primary cancer, either presenting concurrently or on subsequent follow-up, is likely to be increasingly observed. The series of patients reported here highlights the importance of a diagnostic biopsy in patients with malignant melanoma who develop a renal mass in order to establish a diagnosis and to plan optimal treatment.

Sign in / Sign up

Export Citation Format

Share Document